CHALLENGES IN SIX SIGMA IMPLEMENTATION JAKARTA, DECEMBER 7TH, 2017
|
|
- Marjorie Underwood
- 5 years ago
- Views:
Transcription
1 1 CHALLENGES IN SIX SIGMA IMPLEMENTATION JAKARTA, DECEMBER 7TH, 2017 STEN WESTGARD, MS WESTGARD QC, INC
2 3 WHY LISTEN TO THESE GUYS? Father knows best! Son knows better? The Westgard 40+ years at the University of Wisconsin Westgard Rules Method Validation Critical-Error graphs OPSpecs A Westgard 25 years at Westgard QC Publishing Web Blog course portal
3 WHY TAKE ADVANTAGE OF WESTGARD WEB? 4 Blog: >400 Short articles Q&A Website: >56,000 members >3 million views >600+ essays, lessons, QC case studies, reference, resources Course Portal: Training in QC, Method Validation, Risk Analysis, Quality Management
4 6 WHY WORRY ABOUT QC AND QUALITY? Manufacturer SD used for control limits All data within 2 SD. Too good to be true!
5 POOR QC = POOR PATIENT CARE 7 Clinical consequences of erroneous laboratory results that went unnoticed for 10 days Tse Ping Loh, Lennie Chua Lee, Sunil Kumar Sethi et al. J Clin Pathol March 2013, Vol 166, No test error 5 tests in error 63 results in error
6 THE RIGHT QC COULD HAVE CAUGHT THE ERRORS 8 49 patients Affected 4 procedures ordered in error (including CT Scan) 7 patients ordered for retesting 6 misdiagnoses 4 Control 1 Values 4 Control 2 Values
7 9 STAYING IN COMPLIANCE DIDN T KEEP THIS LAB (AND ITS PATIENTS) OUT OF TROUBLE CAP certified JCI certified 2004 Singapore Service Class award 2004 ISO certified Triple ISO certification ISO 9001 ISO ISO Awards and Awards and Awards We need Detailed QC HELP!
8 10 WE MUST WORRY NOT ONLY ABOUT BAD QC ALSO BAD METHODS For 2 YEARS, Mayo Clinic: about 5% of all IGF-1 tests were false positives. If the Mayo Clinic observations are generalized, a laboratory performing 1000 IGF-1 tests/month would be expected to generate around 50 falsepositive results each month. Some of these can be expected to lead to follow-up appointments or further testing and, ultimately, increased financial burden and anxiety for patients. UVA: 8-month period in 2011, 20 abnormally high IGF-1 results in 17 patients that did not agree with clinical findings. In 17 of the 20 samples, the IGF- 1 concentrations measured by a mass spectrometric method were within reference intervals. In 7 of the patients, expensive growth hormone suppression tests were done; the results were within reference intervals in 6, with the result in the seventh nondiagnostic.
9 2015: CLEVELAND CLINIC CATASTROPHE 16 $769,000 fine levied on Cleveland Clinic Marymount Hospital [P]atients in "immediate jeopardy," CMS says Cleveland Plain Dealer September 2015 Failing to run QC Using expired reagent PT/EQA cheating Lab closed for 4 months, 2 weeks; lab director fired CAP inspection in December 2014 missed these problems "Cobas 6000 Instrument Printouts: K- B2014: Sample K-06:. e) Date: 07/27/14 12:54:53 Handwritten notes stated: "COBAS 1 "RERUN" The ID number 6 and date and time were circled. The word rerun was underlined twice. Each numeric results listed below had a checkmark to left. Folate, Seru 1.50 ng/ml Ferritin L ng/ml Free T L ng/dl Quant Beta H H miu/ml TSH L uiu/ml Vitamin B L pg/ml T L ug/dl FT3 III 3.82 pg/ml"
10 WHY WORRY ABOUT A LACK OF TRUENESS IN ALKALINE PHOSPHATASE? 17 Evaluation of the trueness of serum alkaline phosphatase measurement in a group of Italian laboratories, CCLM 2016: aop Braga F, Frusciante E, Infusino I, Aloisio E, Guerra E, Ceriotti F, Panteghini M Instrument Low Bias Med Bias High Bias 1 Cobas Cobas AU Cobas Cobas 6000/ AU AU AU ADVIA Cobas Cobas Vista ARCHITECT c
11 WHY WORRY ABOUT A LACK OF TRUENESS IN 5 COMMON IMMUNOASSAYS? 18 Analytical Bias Exceeding Desirable Quality Goal in 4 out of 5 Common Immunoassays: Results of a Native Single Serum Sample External Quality Assessment Program for Cobalamin, Folate, Ferritin, Thyroid-Stimulating Hormone, and Free T4 Analyses Clin Chem 62: (2016) Kristensen GBB, Rustad P, Berg JP, Aakre KM Method Abbott ARCHITECT Beckman Coulter Unicel Roche Cobas Siemens ADVIA Centaur Cobalamin Meets Goal Fails Goal Meets Goal Meets Goal Folate Meets Goal Meets Goal Meets Goal Meets Goal Ferritin Meets Goal Fails Goal Fails Goal Fails Goal TSH Meets Goal Meets Goal Fails Goal Meets Goal Free T4 Fails Goal Fails Goal Fails Goal Meets Goal Free T4 (reference) Fails Goal Fails Goal Fails Goal Fails Goal
12 WHY ISN T THE FDA (OR SOMEONE) PROTECTING THE PATIENT FROM POOR QUALITY? 19 Conclusion 7-1. The 510(k) clearance process is not intended to evaluate the safety and effectiveness of medical devices with some exceptions. The 510(k) process cannot be transformed into a premarket evaluation of safety and effectiveness as long as the standard for clearance is substantial equivalance to any previously cleared device. Institute of Medicine 2011: Medical Devices and the Public s health: the FDA 510(k) Clearance Process at 35 years, prepublication copy
13 WHY IS THERE A GAP BETWEEN CERTIFICATIONS AND TRUE QUALITY ASSURANCE? 20 Systems without specifics Policies without performance data Aspirations without Achievement Assumptions that all tests are the same??? If we have a quality system without a quality method, without quality practices, are our patients really safe?
14 6 World Class Performance (3.4 DPM) WHERE DO WE START WITH SIX SIGMA? THE CONCEPTS Defects Per Million (DPM) Scale of 0 to 6 (Sigma short-term scale) Sigma is minimum for any business or manufacturing process (66,807 dpm) 5
15 24 Total Allowable Errors (TEa) PT/EQA groups CLIA RCPA Rilibak Biologic Variation Database Ricos Goals SIGMA VP PROGRAM HOW DO WE IDENTIFY THE PERFORMANCE SPECIFICATION?
16 25 HOW DO WE SELECT THE RIGHT PERFORMANCE SPECIFICATION? November 2014: Milan Meeting Draft Milan Consensus : Outcome-based, Clinical Use Goals (HbA1c NGSP guidance) 2: Biologic-based, Ricos Goals 3: State of the Art (CLIA, Rilibak, EQA/PT) Different analytes will get goals from Different models. Ricos Goals are not practical for all tests! In the future, many of these goals will become unreachable Supposedly not a hierarchy merely different models
17 A CONSENSUS ANSWER: SIGMA VP ESTABLISHES GLOBAL TEA GOALS 26 Analyte Recommended Total Allowable Error Goal (TEa %) TEa Source Recommended Critical Decision Level Albumin 10% CLIA Near 2.5 g/dl or 25 U/L Alk Phos 30% CLIA Near 150 U/L ALT 20% CLIA Near 95 U/L Amylase 30% CLIA Near 145 U/L AST 20% CLIA Near 40 U/L Bilirubin, Direct 44.5% Ricos Desirable Near 0.3 mg/dl or 5.13 umol/l Bilirubin, Total 0.4 mg/dl or 20% (greater) (6.84 umol/l or 20%) CLIA Near 3.0 mg/dl or 51.3 umol/l Calcium 1 mg/dl CLIA Near 13.0 mg/dl or 3.24 mmol/l (0.249 mmol/l) Chloride 5% CLIA Near 100 mmol/l Cholesterol 10% CLIA Near 180 mg/dl or 4.68 mmol/l CO2 25% CAP PT Near 25 mmol/l Creatinine Kinase (CK) 30% CLIA Near 275 U/L Creatinine 0.3 mg/dl or 15% (greater) CLIA Near 2.0 mg/dl or 176 umol/l (26.41 umol/l) GGT 22.11% Ricos Desirable Near 85 U/L Glucose 6 mg/dl or 10% (greater) CLIA Near 120 mg/dl or 6.66 mmol/l (0.33 mmol/l) HDL 30% CLIA Near 50 mg/dl or 1.23 mmol/l Iron 20% CLIA Near 75 mg/dl or 13.4 umol/l LDL 20% CLIA Near 100 mg/dl or 2.59 mmol/l LDH 20% CAP Near 170 U/L Lipase 37.88% Ricos Near 45 U/L Magnesium 25% CAP Near 2.5 mg/dl or 1.02 mmol/l Phosphorous 0.3 mg/dl or 10.7% (greater) CAP Near 4.0 mg/dl or 1.29 mmol/l (0.1 mmol/l) Potassium 0.5 mmol/l CLIA Near 2.5 mmol/l Total Protein 10% CLIA Near 5.7 g/dl or 57 mg/dl Sodium 4 mmol/l CLIA Near 115 mmol/l Triglycerides 25% CLIA Near 130 mg/dl or 1.46 mmol/l Urea Nitrogen 2.0 mg/dl or 9% (greater) CLIA Near 40 mg/dl or mmol/l (0.714 mmol) Uric Acid 17% CLIA Near 3.3 mg/dl or umol/l
18 27 HOW DO WE MEASURE (SIX) SIGMA PERFORMANCE? Measure Variation Use existing data Can we measure imprecision (CV)? Can we measure inaccuracy (bias)? Capture this data at critical medical decision levels
19 28 HOW DO YOU GET THE BEST CV AND BIAS? Imprecision 3 months or longer, third party controls, original manufacturer reagent Bias Your mean vs Peer group mean Your mean vs EQA/PT group mean Your mean vs the Package Insert/Target mean (Ideal but generally impractical: vs reference mean)
20 29 True Value HOW DO YOU ACTUALLY CALCULATE SIGMA METRIC? Sigma-metric = (TE a Bias)/CV - TEa + TEa Bias CV defects -6s -5s -4s -3s -2s -1s 0s 1s 2s 3s 4s 5s 6s
21 How do you select the appropriate level for Sigma? 3 levels of cholesterol method, Clin Chem July 2014 CLIA PT criterion for acceptability = 10% Total Precision (CV): 1.0% 0.9% 1.0% Bias : 3.0% 2.5% 2.3% Sigma = (10 3) / 1.0 = 7.0 / 1.0 = 7.0 Sigma = (10-2.5) / 0.9 = 7.5 / 0.9 = 8.3 Sigma = (10 2.3) / 1.0 Average Sigma = ( ) / 3 = 7.67 = 7.7 / 1.0 = 7.7
22 COMPARISON OF 6 COMPETITORS ON 8 CHEMISTRY ANALYTES 20 patient serum samples Comparison against reference methods or all-method-trimmed-mean Additionally, large laboratory effects were observed that caused interlaboratory differences >30%. There is a need for improvement even for simple clinical chemistry analytes. In particular, the interchangeability of results remains jeopardized by assay standardization issues and individual laboratory effects.
23 SIGMA EVALUATION OF RESULTS Test Abbott Beckman Ortho Roche Siemens Thermo Cholesterol Creatinine Glucose HDL LDL 5.41 n/a n/a Phosphate n/a Uric Acid Triglycerides Average Sigma-metric calculated of 3 levels measured Approximately 10 labs for each instrument CLIA goals used
24 STANDARDIZATION CONCLUSION Given conditions: achieving >6-Sigma performance or highest performance among competitors: Abbott: 6 of 8 analytes Beckman: 4 of 7 analytes Ortho: 3 of 7 analytes Roche: 3 of 8 analytes ThermoFisher: 3 of 7 analytes Siemens: 2 of 8 analytes
25 HOW DO YOU ASSESS SIGMA METRIC VISUALLY? 36
26 CS-6400 CHEMISTRY ANALYZER Evaluation of the CS-6400 Automated Chemistry Analyzer. Hyo-Jun Ahn, Hye-Ryun Kim, and Young- Kyu Sun, J Lab Med Qual Assur 2013;35: Assay TEa Level 1 CV% Bias% TEa Level 2 CV% Bias% Albumin 10% % 4.37% 10% % 10.26% Alk Phos 30% % % 30% % % AST 20% % 12.12% 20% % 10.13% ALT 20% % 18.65% 20% % 19.93% Amylase 30% % % 30% % % Bilirubin, Direct 44.5% % 12.93% 44.5% % 27.51% Bilirubin, Total 63.5% % 12.63% 20.0% % 5.04% Calcium 15.48% % 0.36% 10.54% % 6.17% Cholesterol 10% % 3.88% 10% % 4.63% Creatinine Kinase (CK) 30% % 13.07% 30% % 13.71% Chloride 5% % 0.05% 5% % 0.42% Creatinine 25.21% % 10.92% 15% % 0.29% GGT 22.11% % 32.92% 22.11% % 32.76% Glucose 10% % 6.53% 10% % 4.76% HDL 30% % 13.94% 30% % 15.66% Potassium 18.05% % 5.56% 11.42% % 2.55% Sodium 2.65% % 1.24% 2.84% % 1.64% Phosphate 10.7% % 2.29% 10.7% % 1.31% Total Protein 10% % 7.59% 10% % 8.26% Triglycerides 25% % 8.78% 25% % 18.98% Urea Nitrogen 9% % 19.85% 9% % 5.0% Uric Acid 17% % 8.14% 17% % 10.85% LDH 20% % % 20% % % Magnesium 25% % 9.70% 25% % 4.46% LDL 20% % 4.65% 20% % 6.31% Lipase 37.44% % 53.91% 37.44% % %
27 DISPLAY OF SIGMA-METRICS: NORMALIZED METHOD DECISION CHART (26 TESTS) 39
28 40 Importance of implementing an analytical quality control system in a core laboratory, Marques-Garcia F, Garcia-Codesal F, del Rosario Caro-Narros M, Contreras-San Feliciano T, Revista de Caldidad Asistencial 2015 Nov- Dec;30(6): methods
29 48 SMALL VOLUME CHEMISTRY ANALYZER 23 of 25 tests are >5 Sigma 92% of assays Kern Valley Hospital District (25 methods) >6 Sigma: Sodium Potassium Chloride Creatinine Total Protein Albumin Alk Phos ALT AST Total Bilirubin Direct Bilirubin Amylase Lipase CK Phosphorus Iron Uric Acid Cholesterol Triglycerides HDL
30 HOW DO YOU USE THE SIGMA METRIC TO IMPROVE YOUR LAB? THE OPSPECS CHART 49 Free download at
31 OPSPECS QC DESIGN FOR CS-6400 ANALYZER
32 COBAS 8000 QC DESIGN 51
33 53 QC DESIGN FOR KERN VALLEY
34 63 SIX SIGMA IS AN INCREASINGLY IMPORTANT TECHNIQUE FOR LABS AROUND THE WORLD IFCC committee on HbA1c standardization recommends Six Sigma as the way to judge assay quality. Clin Chem May;61(5): doi: /clinchem Epub 2015 Mar 3. Investigation of 2 models to set and evaluate quality targets for hb a1c: biological variation and sigma-metrics. Weykamp C 1, John G 2, Gillery P 3, English E 4, Ji L 5, Lenters-Westra E 6, Little RR 7, Roglic G 8, Sacks DB 9, Takei I 10 ; IFCC Task Force on Implementation of HbA1c Standardization. IFCC / EFLM committee on Pre-analytical and Post-analytical Quality Indicators recommends benchmarking on the Sigma scale Clin Chem Lab Med May;53(6): doi: /cclm Performance criteria and quality indicators for the pre-analytical phase. Plebani M, Sciacovelli L, Aita A, Pelloso M, Chiozza ML. Collective Opinion Paper 2013/2015 in Australian recommends adoption of Six Sigma metrics Collective Opinion Paper on a 2013 AACB Workshop of Experts seeking Harmonisation of Approaches to Setting a Laboratory Quality Control Policy Graham Jones John Calleja Douglas Chesher Curtis Parvin John Yundt-Pacheco Mark Mackay Tony Badrick Clin Biochem Rev 36 (3) 2015 Belgian EQA program offers Sigma-metrics to their participants Clin Chem Lab Med Feb 9. pii: /j/cclm.ahead-of-print/cclm /cclm xml. doi: /cclm [Epub ahead of print] Expressing analytical performance from multi-sample evaluation in laboratory EQA. Thelen MH, Jansen RT, Weykamp CW, Steigstra H, Meijer R, Cobbaert CM. Sigma-metrics calculated by Bio-Rad, Randox, MAS, and Technopath
35 HOW DOES IT IMPACT OUR DECISIONS? IFCC COMPARISON OF MAJOR HBA1C METHODS 64 Bias assessed using Accuracy-based materials across 8 levels of HbA1c Performance comparing Tosoh Bio-Rad Variant Turbo 2.0 Roche ARCHITECT enzymatic
36 65 HBA1C SIX SIGMA PERFORMANCE
37 HOW TO QC HBA1C 66
38 UNDERSTANDING THE IMPACT OF LABORATORY PERFORMANCE ON OUTCOMES IN A SCREENING POPULATION FOR CARDIOVASCULAR Wu L 1, Jülicher P 2, Liu L 3 DISEASE IN TAIWAN 1 ChiMei Medical Center, Tainan, Taiwan; 2 Abbott Diagnostics, Wiesbaden, Germany; 3 ChiMei Medical Center, Health Management Center, Tainan, Taiwan ISPOR 7 th Asia-Pacific Conference, 3-6 September 2016, Singapore Data were collected from 1,396 people (Age >=40 years) enrolled for CVD screening between January and April 2015 in Tainan (Table 1). A time-to-event microsimulation model was developed (Figure 1). Starting with screening, each individual was classified into risk categories based on observed values for LDL-, HDL-, total cholesterol, and a 10-years CVD risk score. Patients with observed values of LDL 190mg/L, 70<LDL<190 and a risk score 7.5%, and diabetic patients with LDL between 70 and 190 plus a risk score between 5 and 7.5% were referred for treatment. They received lipid lowering drugs thus reducing risk for a CVD event. Individuals not assigned to treatment remained in the No treatment - state until the next screening cycle after 1-4 years, the occurrence of a CVD event, or death. Minimum and optimum test specifications as suggested in literature were tested against a control scenario assuming perfect performances (Table 2). Samples were bootstrapped from the cohort with 100,000 iterations. Model followed a lifetime Table 2. Test horizon performance andof acomparing health strategies system perspective. Results were expressed in costs, quality adjusted life-years (QALY), Total and -C relative over- HDL-C or under-treatment. LDL-C Model was tested in 1- Strategy Bias, % CV, % Bias, % CV, % Bias, % CV, % Source way and probabilistic sensitivity analysis. Introduction Risk scores for cardiovascular disease (CVD) events based on laboratory values have been established in primary prevention programs [1]. The performance of laboratory test systems may lead to discordant treatment decisions in some cases. The goal of this study was to investigate the impact of laboratory diagnostic system performance on outcomes in a screening population for CVD in Taiwan. Mimimun (MIN) [16,17] Optimum (OPT) Control (CON) Assumption Results in terms of incremental values compared to the control scenario are summarized in Table 2. Analytical measurement uncertainty caused by CV and bias resulted in discordant management in some cases. The MIN and OPT strategy led to different decisions in 14.1% and 4.1%, respectively. Patients who had not received preventive treatment based on erroneous results had a higher risk for CVD events at an earlier time. The observed strategies showed a small but significantly increased number of CVD events and CVD related deaths compared to the control. MIN resulted in a loss of life years (LY) of 131 significant p. 1,000 for subjects MIN but not for OPT. Table 2. Incremental results from microsimulation. Figure 2. Incremental costs and QALY per strategy compared to the Control. Microsimulation with 100,000 samples. Mean, 95%CI of Δ Costs per patient, and Δ QALY per 1,000 subjects. Minimum strategy (MIN), Optimum strategy (OPT), Control strategy (CON) as defined in Table 2. *Per 1,000 individuals screened. MIN vs. CON OPT vs. CON MIN vs.opt Outcome value Mean (95%CI) Mean 95%CI Mean 95%CI Δ Costs per patient, NT$ 8753 (7516; 9990) 2075 (844; 3307) 6678 Δ QALY* The selection of high performance -56 diagnostic (-96; systems -17) plus -21 a strict quality (-60; 18) control management -36 in Methods Figure 1. Time-to-event microsimulation model structure Δ Total LY* -131 (-220; -43) -33 (-122; 55) -98 Results are limited to the information derived from the cohort. Risk scores may not accurately estimate the actual risk. Patient characteristics were sampled from distributions in order to reflect variability and uncertainty. The model assumed a stable lipid status over the time span of the simulation. Acknowledgement We thank Roger Low and Sten Westgard for motivation and fruitful discussions. Table 1. Characteristics of screening cohort (n=1,396) per 1,000 subjects (95%CI 43, 220), whereas a non-significant trend was observed for the OPT performance. Loss in QALY resulting from unnecessary treatment, earlier and increased risk for events, or increased mortality was found to be CVD related life-time costs were significantly higher compared to CON for MIN (+NT$ 8,753) and OPT (+NT$ 2,075). Conclusions Analytical measurement uncertainty may impose a higher risk for missing prevention opportunities. the laboratory conforming to the optimum specification is critical to consistently providing high and efficient quality of care. Limitations Variable Mean (SE) Sex (% women) 35.9 Age, years* 52.9 (40-85) BMI 24.2 (0.1) Pulse 72.9 (0.3) BPSys (mmhg) (0.5) BPDia (mmhg) 74.2 (0.3) GLUC_FAST (0.8) TCHOL (mg/dl) (1.0) HDL-C (mg/dl) 54.7 (0.4) LDL-C (mg/dl) (0.9) Results ( ; ) ; 3 ) ( ; ) ( Variable Value Distribution Source Setting, risk & events CVD risk (10 years) Risk based equations [1] In-hospital mortality from stroke 10.1 Beta [2] In-hospital mortality from AMI 6.5 Beta [3] Mortality from stroke at 1 year, % 12.0 Weibull [2] Mortality from MI at 1 year, % 6.0 Weibull [4] Mortality (non-cvd) Age-, sex-specific lifetable Weibull [5] Annual risk for recurrent CVD, % 6.8 Weibull [4] Risk reduction under treatment, % (95%CI) 65 (58, 73) Uniform [6] CVD event type (Stroke vs. MI), % 76 Beta [7] Smoking prevalence Male, % (95%CI) 31 (28.0, 35.2) Uniform [8] Smoking prevalence Female, % (95%CI) 3.4 (2.8, 4.2) Uniform [8] Laboratory results Mean from cohort Normal Assumption Screening cycle, years 1 to 4 Uniform Assumption Utility Baseline Beta [9] Lipid lowering treatment, Mean (SD) (0.001) Beta [10] MI (disutility), Mean (SD) (0.048) Beta [9] Stroke (disutility), Mean (SD) (0.039) Beta [9] Post MI (0.010) Beta [9] Post stroke (0.010) Beta [9] Costs, NT$ 1,2 Screening & visit 5,585 Uniform [11] Permanent lipid lowering treatment 15,639 Uniform [12] Stroke 74,832 Uniform [13] Post-stroke 45,630 Uniform [14] MI 189,497 Uniform [15] Post MI 82,897 Uniform [14] Annual discount rate for costs and utility, % 3.0 Table 3. Model input assumptions. (1) All costs adjusted for inflation with a 3% rate to 2015 New Taiwan dollar.(2) A range of ±25% was used to create upper and lower bounds. The Minimum and Optimum strategy led to higher costs compared to the Control for 32% and 27%, respectively (Fig. 3). As revealed from a sensitivity analysis, for each increase in percent point of CV, negative or positive bias 22, 43 or 7 individuals per 1,000 screened subjects would be either over- or under-treated compared to the control (Fig. 4, Tab. 3). Negative bias particularly increased the risk for denying preventive treatment, and would affect six times more patients than positive bias. Incremental costs per patients caused from discordant management decisions and related consequences would accrue Table 3. Impact of CV and bias on over- and under-treated individuals, and incremental to NT$786 (96%CI 734;838), NT$762 (612;912) and NT$699 costs. OT/ (668;729) UT: Over-/Under-treated; per percent Data increase based on linear in regression negative model. bias, Sensitivity positive analyses bias and assumed CV, respectively perfect %CV or (Tab. bias. 3). Variable Response Coeff. (95%CI) R-Sq, % (-) bias ΔUT, per 1,000 subjects 43.3 (40.6; 45.9) ΔCosts, NT$ 786 (734;838) (+) bias ΔOT, per 1,000 subjects 6.5 (5.6;7.3) References Figure 3. Distribution of incremental costs (IC) per strategy. Figure 4. Impact of increasing Bias and CV on discordant treatments. OT: Over-treated; UT: Under-treated. No significant deviation from the Control strategy was observed for both, the number of individuals over-treated with increasing negative bias, and the number of individuals under-treated with increasing positive bias 1. Stone NJ, Robinson JG, Lichtenstein AH, et al ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129(25 Suppl 2):S Lee HC, Chang KC, Huang YC, et al. Readmission, mortality, and first-year medical costs after stroke. JCMA. 2013;76(12): Yin WH, Lu TH, ΔCosts, Chen NT$ KC, et al. The temporal trends of incidence, 762 treatment, (612; 912) and in-hospital mortality of acute myocardial infarction over 15years in a Taiwanese population. Int J Card. 2016;209: Chiang FT, Shyu KG, Wu CJ, et al. Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. J Formos Med Assoc. 2014;113(11): Ministry of Interior, Department of Statistics, Taiwan. Liftetable Accessed May 18, CV Taylor F, Huffman ΔUT, M, per Macedo 1,000 subjects A, et al. Statins for the primary 10.2 prevention (9.8;10.6) of cardiovascular disease. The Cochrane database of systematic reviews. 2013(1). 7. Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Card. 2015;201: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, JAMA. 2014; 311(2): Kang EJ, Ko SK. ΔOT, A catalogue per 1,000 subjects of EQ-5D utility weights for 12.1 chronic diseases (11.8;12.5) among noninstitutionalized community residents in Korea. Value Health. 2009;12 Suppl 3:S Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015;314(2): Lin YK, Chen CP, Tsai WC, Chiao YC, Lin BY. Cost-effectiveness of clinical pathway in coronary artery bypass surgery. J Med Sys. 2011;35(2): Cobiac LJ, Magnus ΔCosts, A, NT$ Barendregt JJ, Carter R, Vos T. Improving 699 the (668;729) cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012;12(389). 13.Lien HM, Chou SY, Liu JT. Hospital ownership and performance: evidence from stroke and cardiac treatment in Taiwan. J Health Econ. 2008;27(5): Chung CW, Wang JD, Yu CF, Yang MC. Lifetime medical expenditure and life expectancy lost attributable to smoking through major smoking related diseases in Taiwan. Tob Control.
39 78 HEALTH ECONOMICS OUTCOMES OF OPTIMAL SIX SIGMA QUALITY A time-to-event microsimulation model was developed. Starting with screening, each individual was classified into risk categories based on observed values for LDL-, HDL-, total cholesterol, and a 10- years CVD risk score. Patients with observed values of LDL 190mg/L, 70<LDL<190 and a risk score 7.5%, and diabetic patients with LDL between 70 and 190 plus a risk score between 5 and 7.5% were referred for treatment. They received lipid lowering drugs thus reducing risk for a CVD event. Individuals not assigned to treatment remained in the No treatment - state until the next screening cycle after 1-4 years, the occurrence of a CVD event, or death. Minimum and optimum test specifications as suggested in literature were tested against a control scenario assuming perfect performances. Samples were bootstrapped from the cohort with 100,000 iterations. Model followed a lifetime horizon and a health system perspective. Results were expressed in costs, quality adjusted life-years (QALY), and relative over- or under-treatment. Model was tested in 1-way and probabilistic sensitivity
40 79 The Minimum and Optimum strategy led to higher costs compared to the Control for 32% and 27%, respectively (Fig. 3). As revealed from a sensitivity analysis, for each increase in percent point of CV, negative or positive bias 22, 43 or 7 individuals per 1,000 screened subjects would be either over- or under-treated compared to the control.negative bias particularly increased the risk for denying preventive treatment, and would affect six times more patients than positive bias. HOW SIX SIGMA METHODS IMPACT QC AND PATIENT OUTCOMES Incremental costs per patients caused from discordant management decisions and related consequences would accrue to NT$786 (96%CI 734;838), NT$762 (612;912) and NT$699 (668;729) per percent increase in negative bias, positive bias and CV, respectively
41 80 HOW SIX SIGMA METHODS IMPACT QC AND PATIENT OUTCOMES Results in terms of incremental values compared to the control scenario are summarized in Table 2. Analytical measurement uncertainty caused by CV and bias resulted in discordant management in some cases. The MIN and OPT strategy led to different decisions in 14.1% and 4.1%, respectively. Patients who had not received preventive treatment based on erroneous results had a higher risk for CVD events at an earlier time. The observed strategies showed a small but significantly increased number of CVD events and CVD related deaths compared to the control. MIN resulted in a loss of life years (LY) of 131 p. 1,000 subjects (95%CI 43, 220), whereas a non-significant trend was observed for the OPT performance. Loss in QALY resulting from unnecessary treatment, earlier and increased risk for events, or increased mortality was found to be significant for MIN but not for OPT. CVD related life-time costs were significantly higher compared to CON for MIN (+NT$ 8,753) and OPT (+NT$ 2,075). Figure 2. Incremental costs and QALY per strategy compared to the Control. Microsimulation with 100,000 samples. Mean, 95%CI of Δ Costs per patient, and Δ QALY per 1,000 subjects.
42 81 CLINICAL IMPACT SIMULATION MATCHES HEALTH ECONOMIC STUDY RESULTS Method differences result in risk SCORE misclassifications Method HDLc median Mmol/L CV% Bias Mmol/L Men Risk SCORE Wrong class SCORE>5 Abbott Beckman % Olympus Roche % Siemens % Laboratories supporting lipid clinics with a high proportion of specimens with atypical lipoproteins could observe discrepant results on certain specimens that might confound treatment decisions. It is vitally important for clinical laboratories to consider assay reliability and specificity when choosing methods, particularly in dyslipidemic samples.
43 100 CONCLUSION Six Sigma Implementation is not Simple, but it can be Simplified Use the Westgard Six Sigma tools to allow the laboratory to Identify the RIGHT method Select the RIGHT rules Run the RIGHT number of controls Run the controls at the RIGHT time and frequency next!
44 101 HOW DO WE MAKE THE SIGMA IMPLEMENTATION EASIER TO IMPLEMENT? SIGMA VP PROGRAM
45 102 THANK YOU FOR YOUR KIND ATTENTION! (QUESTIONS?)
CONSULTORIAS INTEGRALS EN CALIDAD S.A.S. STEN WESTGARD, WESTGARD QC
1 CONSULTORIAS INTEGRALS EN CALIDAD S.A.S. STEN WESTGARD, WESTGARD QC 2 HOW DO WE IMPROVE HEALTHCARE? Recognize where we are QC skill deficits Manufacturer letdowns Adopt tools for assessment and improvement
More informationRethinking Traditional Lab QA/QC:
Rethinking Traditional Lab QA/QC: Understanding Weaknesses in Existing Requirements and Mastering Useful Methods and Metrics to Raise Your Lab s Analytical Accuracy October 1 st, 2013 Laboratory Quality
More informationWestgard Rules. The Evolution of QC STEN A WESTGARD WESTGARD QC, INC. MADISON, WI USA
WESTGARD RULES 1 2 Westgard Rules The Evolution of QC STEN A WESTGARD WESTGARD QC, INC. MADISON, WI USA WWW.WESTGARD.COM 3 THE QUEST FOR QUALITY How long have we running QC? More than half a century! (So
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
More informationReference Intervals. Graham Jones / Gus Koerbin
Reference Intervals Graham Jones / Gus Koerbin Adult CRI - Harmonisation Harmonisation 1 2012: (13 tests + 1 calculation) Harmonisation 2 2013: Confirm 2012 recommendations. Discussed: albumin, globulin,
More informationSetting of quality standards
Setting of quality standards Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney AACB ASM Adelaide October 2014 Setting of Quality Standards - 2013 The 2013 QC workshop revealed
More informationEvaluation of VACUETTE CAT Serum Fast Separator Blood Collection Tube for Routine Chemistry Analytes in Comparison to VACUTAINER RST Tube
Evaluation of VACUETTE CAT Serum Fast Separator Blood Collection Tube for Routine Chemistry Analytes in Comparison to VACUTAINER RST Tube Background: Greiner-Bio-One, Austria has been selling plastic evacuated
More informationENROLLMENT CONFIRMATION
Step 1: Please review the Facility/Contact information. If any of the information is incorrect, please make the appropriate changes below: Facility/Contact Phone: (850)474-3660 Fax: (850)474-3659 6431
More informationEvidence Based Commutability: Bias 2 Study. Janice Gill Manager RCPAQAP Chemical Pathology Adelaide SA
Evidence Based Commutability: Bias 2 Study Janice Gill Manager RCPAQAP Chemical Pathology Adelaide SA Australian Bias Studies conducted by Gus Koerbin, ACT Pathology on behalf of AACB Harmonisation Committee
More informationEvaluation of new MiniCollect Z Serum (Separator) Tubes
Evaluation of new MiniCollect Z Serum (Separator) Tubes Background: Greiner Bio-One has developed a newly designed MiniCollect tube offering an integrated collection scoop. The advantage of the new tube
More informationCommutability studies undertaken by the LNE : the case of lipid and lipoprotein testing. Vincent Delatour, PhD
Commutability studies undertaken by the LNE : the case of lipid and lipoprotein testing Vincent Delatour, PhD 1 Traceability in laboratory medicine : regulatory drivers Reform of medical biology in France
More informationComparison of VACUETTE Heparin Gel Tubes for Common Chemistry Analytes
Comparison of VACUETTE Heparin Gel Tubes for Common Chemistry Analytes Background: Greiner-Bio-One, Austria has been selling plastic evacuated tubes (VACUETTE ) for venous blood collection since 9. The
More informationGeneral Chemistry Scheme Guide
General Chemistry Scheme Guide Copyright WEQAS. All rights reserved. No part of this document may be reproduced or utilised in any form without permission from WEQAS Contents. Scheme details and repertoire.....
More informationStability of VACUETTE Lithium Heparin Separator tubes with modified centrifugation conditions
Stability of VACUETTE Lithium Heparin Separator tubes with modified centrifugation conditions Background: Greiner-Bio-One, Austria has been selling plastic evacuated tubes (VACUETTE ) for venous blood
More informationMETHOD VALIDATION: WHY, HOW AND WHEN?
METHOD VALIDATION: WHY, HOW AND WHEN? Linear-Data Plotter a,b s y/x,r Regression Statistics mean SD,CV Distribution Statistics Comparison Plot Histogram Plot SD Calculator Bias SD Diff t Paired t-test
More informationWSLH. Calibration Verification/ Linearity Products. roficiency. esting. Products provided in partnership with:
WSLH PT roficiency esting Calibration Verification/ Linearity Products Products provided in partnership with: www.wslhpt.org 800-462-5261 PTService@slh.wisc.edu General Chemistry Ammonia/Ethanol - 5 x
More informationCollege of American Pathologists (CAP) GH2 Survey Data: (updated 12/09) 2009 GH2-B (fresh pooled samples) * = NGSP certified at the time of the survey
College of American Pathologists (CAP) GH2 Survey Data: (updated 12/09) The American Diabetes Association (ADA) recommends that laboratories use only HbA1c assay methods that have been NGSP certified and
More informationROTUNDA HOSPITAL DEPARTMENT OF LABORATORY MEDICINE
This active test table informs the user of Biochemistry tests available in house. s referred to other sites are recorded in the Referred Table. Issue date: 4 TH April 2016 Contact Phone Number ext.1345/2522
More informationBio-Rad Laboratories. Cardiac Assessment Controls. Value Assigned for Clinical Laboratory and Point of Care Test Systems
Bio-Rad Laboratories Cardiac Assessment Controls Cardiac Assessment Controls Value Assigned for Clinical Laboratory and Point of Care Test Systems Solving the Challenges of Troponin I Testing for the Central
More informationCardiac Assessment Controls
Bio-Rad Laboratories CARDIAC ASSESSMENT CONTROLS Cardiac Assessment Controls Value Assigned for Clinical Laboratory and Point of Care Test Systems Solving the Challenges of Troponin I Testing for the Central
More informationFaculty/Presenter Disclosure I WOULD NEVER ORDER THAT FOR THAT PERSON; LAB USE AND MISUSE IN ALBERTA 19/10/2016
I WOULD NEVER ORDER THAT FOR THAT PERSON; LAB USE AND MISUSE IN ALBERTA Trefor Higgins DynaLIFEDx Edmonton, Alberta Faculty/Presenter Disclosure Presenter: Trefor Higgins Relationships that may introduce
More informationTotal Cost of Ownership (TCO): An evidence-based approach to compare laboratory equipment
Total Cost of Ownership (TCO): An evidence-based approach to compare laboratory equipment P.C.G. Gontard 1, L.I. Stankevich 1, B.G. Gorodetsky 1 SUMMARY Clinical laboratories across the globe operate in
More informationBiochemistry Adult Reference Ranges
Certified correct on 28/06/2016 Biochemistry Adult Reference Ranges Test Reference range Units Reference range from Traceable to standard reference material Albumin 35 50 g/l Pathology IRMM ERM-DA470k/IFCC
More informationTables of Normal Values (As of February 2005)
Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal
More informationSerodos and Serodos plus
Design Verification Serodos and Serodos plus Contents 1 Value Adjustment... 2 2 Target Determination... 2 3 Stability... 2 Real-Time Stability... 3 Stability after Reconstitution... 4 Stability after Reconstitution
More information(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)
cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care
More informationControls & Calibrators Clinical Chemistry
Controls & Calibrators Clinical Chemistry Clinical Chemistry Controls & Lipids Clinical Chemistry and lipid quality controls have been manufactured from true human serum to ensure they perform the same
More informationAnalytical performance specifications two years after Milan conference. Prof Mauro Panteghini CIRME Scientific Coordinator
Analytical performance specifications two years after Milan conference Prof Mauro Panteghini CIRME Scientific Coordinator Definition Analytical performance specifications: Criteria that specify (in numerical
More informationTRENDS IN TIME. EXTERNAL EVALUATION PROGRAM FOR Immmunoassays - Chemistry
Commissie voor Klinische Biologie Commission de Biologie Clinique EXTERNAL EVALUATION PROGRAM FOR Immmunoassays - Chemistry TRENDS IN TIME CM Van Campenhout N Hamers JC Libeer WIV/ISP/IPH Clinical Biology
More informationCommentary by R. Little, Ph.D., NGSP Network Coordinator for the NGSP Steering Committee
College of American Pathologists (CAP) GH5 Survey Data: (updated 8/17) The American Diabetes Association (ADA) recommends that The A1C test should be performed using a method that is certified by the NGSP.
More informationCommentary by R. Little, Ph.D., NGSP Network Coordinator for the NGSP Steering Committee
College of American Pathologists (CAP) GH5 Survey Data: (updated 12/17) The American Diabetes Association (ADA) recommends that The A1C test should be performed using a method that is certified by the
More informationSelecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan
729488DSTXXX10.1177/1932296817729488Journal of Diabetes Science and TechnologyWestgard et al research-article2017 Original Article Selecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan Journal
More informationImpact of Proposed HRI s on Laboratory Report Flagging Rates
Impact of Proposed HRI s on Laboratory Report Flagging Rates A/Prof. Ken Sikaris Melbourne Pathology BSc(Hons), MBBS, FRCPA, FAACB, FFSc CBN 2011 WORKSHOP 2012 WORKSHOP 2013 WORKSHOP 2014 GENERAL CONCEPTS
More informationCardiac Assessment Controls A critical element of reliable cardiac testing
Cardiac Assessment Controls Cardiac Assessment Controls A critical element of reliable cardiac testing Choose the products best suited for your cardiac assessment needs Each year, 17.7 million people on
More informationTraceability in External Quality Assessment: How Weqas ensures traceability in EQA and stresses its importance to users. David Ducroq.
Traceability in External Quality Assessment: How Weqas ensures traceability in EQA and stresses its importance to users David Ducroq Weqas Unit 6, Parc Tŷ Glas Llanishen Cardiff UK www.weqas.com Programme
More informationManufacturer Report for Siemens Unassayed Chemistry Lot Exp 30 Jun 2018
Acetaminophen Enzymatic, colorimetric µg/ml.09 0..0.09 0..0 0. 0. 0. 0. 9.. 9.0 0.9.0..9.. Albumin Bromcresol Purple (BCP) g/dl.0 0.0..0 0.00.. 0.0.. 0.09..9 0.0..9 0.0..0 0.0..0 0.0. Alkaline Phosphatase
More informationRethinking Tradi.onal QA/QC: Weaknesses of Current Prac.ces; Six Sigma Metrics and Tools for Improvement
Rethinking Tradi.onal QA/QC: Weaknesses of Current Prac.ces; Six Sigma Metrics and Tools for Improvement James O. Westgard Sten A. Westgard Westgard QC, Inc. Madison, WI www.westgard.com 1 Hospitals recognize
More informationMEMORANDUM. These reference ranges are effective immediately but sample requirements remain unchanged currently.
MEMORANDUM Originating Department Chemical Pathology Issued By: Issued To: Subject: Details: Dr. Shari Srinivasan All Laboratory Service Users Change in Chemical Pathology Analysers Dear Colleague, As
More informationAina Blood Monitoring System
Aina Blood Monitoring System Analytical Performance Summary The Aina Blood Monitoring System is a high quality and versatile multi-parameter diagnostic platform that is CE-marked and approved for sale
More informationAnalyte Specimen Demographic Reference Range Units
Acetone Negative titer Alanine aminotransferase (ALT/SGPT) 10-49 U/L Albumin 3.2-4.8 g/dl Alcohol < 10 Alpha-fetoprotein (AFP) < 1.3-8.1 ng/ml Alkaline phosphatase 0 7 days 7 30 days 1 3 3 6 6 12 1 3 3
More informationDaily Quality Control Calibration Verification / Linearity. Quality control made easy. Product Information
Daily Quality Control Calibration Verification / Linearity Quality control made easy. Product Information AUDIT MicroControls Making life in the lab easier. AUDIT provides value to customers through high-quality
More informationExternal Quality Assessment for Calibration Laboratories in Laboratory Medicine - RELA -
External Quality Assessment for Calibration Laboratories in Laboratory Medicine - RELA - Anja Kessler Bonn, Germany 1 RELA Surveys www.dgkl-rfb.de 2 RELA Annual Process Each participant receives two different
More informationState of the Art of HbA1c Measurement
State of the Art of HbA1c Measurement XXI Congreso Latinoamericano de Patologia Clinica Y XLII Congreso Mexicano de Patologia Clinica, Cancun October 2012 Randie R. Little, Ph.D. NGSP Network Laboratory
More informationCoping with Analytical Interferences
Coping with Analytical Interferences (Handling Icteric, Hemolytic and Lipaemic Samples) Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney Surabaya Indonesia 2016 Acknowledgements
More informationAUSTRALIAN PATHOLOGY UNITS AND TERMINOLOGY (APUTS) Harmonised Reference Intervals Chemical Pathology. (v1.1)
AUSTRALIAN PATHOLOGY UNITS AND TERMINOLOGY (APUTS) Harmonised Reference Intervals Chemical Pathology (v1.1) ISBN: Pending 1 State Health Publication Number (SHPN): Pending Online copyright RCPA 2014 This
More informationAuthorised: JSWoodford, Lead of Speciality. Biochemistry Reference Intervals, October Page 1 of 5
AFP All All < 15 ug/l Albumin All 0-3M 25-40 g/l Albumin All 3-12M 32-45 g/l Albumin All 1-70Y 34-48 g/l Albumin All >70Y 32-46 g/l Alk Phos All 0-10Y 80-350 U/L Alk Phos M 10-14Y 45-400 U/L Alk Phos F
More informationCME/SAM. An Examination of the Usefulness of Repeat Testing Practices in a Large Hospital Clinical Chemistry Laboratory
Clinical Chemistry / Repeat Testing Practices in Clinical Chemistry An Examination of the Usefulness of Repeat Testing Practices in a Large Hospital Clinical Chemistry Laboratory Carl O. Deetz, MD, PhD,
More informationQuality Initiative In Pathology. Harmonisation of Laboratory Testing
Quality Initiative In Pathology Harmonisation of Laboratory Testing Harmonisation: what do we mean? Agreement of test results irrespective of the method used or the testing laboratory Requires: Common
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationEvidence Based HbA1c Accuracy. Sabrina Koetsier Medical Scientist RCPAQAP Chemical Pathology
Evidence Based HbA1c Accuracy Sabrina Koetsier Medical Scientist RCPAQAP Chemical Pathology Fresh lycohaemoglobin This program is designed to assist laboratories to assess the accuracy of their hihba1c
More informationGlobal Report #01 27/11/2013. Patient percentile monitoring compared to internal quality control (IQC) monitoring
Patient Percentile Monitoring Global Report #01 CONTENT Project status Patient percentile monitoring compared to internal quality control (IQC) monitoring Comparison of outpatient/all patient monitoring
More informationHamilton Regional Laboratory Medicine Program
Created: April 2002 of Review: February 2004 of Review: June 2006 of Review: July 2007, St. Joseph s Healthcare went live with Meditech as of June18, 2007. of Review: August 2009 of Review: December 2011;
More informationHamilton Regional Laboratory Medicine Program
Created: April 2002 of Review: February 2004 of Review: June 2006 of Review: July 2007, St. Joseph s Healthcare went live with Meditech as of June18, 2007. of Review: August 2009 of Review: December 2011;
More informationThe order of draw - myth or science? Dr Mike Cornes: Principal Clinical Scientist Royal Wolverhampton NHS Trust
The order of draw - myth or science? Dr Mike Cornes: Principal Clinical Scientist Royal Wolverhampton NHS Trust Where is Wolverhampton? Samples Errors Where is Order of draw Important? Problems Associated
More informationAnalytical Performance in the The Test Evaluation Cycle
Analytical Performance Specifications based on Outcome Studies: Is it possible? Test Evaluation Working Group of EFLM www.efcclm.eu SEALS Department of Clinical Chemistry, Prince of Wales Hospital, Sydney
More information1 PROTOCOL. Comparison Study Summary. Springs Memorial Hospital. Springs Memorial Hospital 800 W. Meeting St. Lancaster, SC (803)
Comparison Study Summary Springs Memorial Hospital 800 W. Meeting St. Lancaster, SC 29720 (803) 286-1480 February 10, 2016 1 PROTOCOL This evaluation was conducted on February 10, 2016 at Springs Memorial
More information10 Essential Blood Tests PART 1
Presents 10 Essential Blood Tests PART 1 The Blood Chemistry Webinars With DR. DICKEN WEATHERBY Creator of the Blood Chemistry Software Essential Blood Test #1: Basic Chem Screen and CBC http://bloodchemsoftware.com
More informationMore to Life. Where research becomes the basis of discovering newer ways of alleviating human suffering and empowering an individual with good health.
More to Life Where research becomes the basis of discovering newer ways of alleviating human suffering and empowering an individual with good health. Meril Diagnostics Emerging from a lineage of successful
More informationNORMAL LABORATORY VALUES FOR CHILDREN
Pediatric Drug Lookup Normal Laboratory Values for NORMAL LABORATORY VALUES FOR CHILDREN CHEMISTRY Normal Values Albumin 0-1 y 2.0-4.0 g/dl 1 y to adult 3.5-5.5 g/dl Ammonia Newborns 90-150 mcg/dl 40-120
More informationVITROS MicroSlide Assay Summary
ACET Acetaminophen ALB Albumin EDTA 10 9 TDM PV Specialty 5.5 4 PV Isotonic saline or 10 200 μg/ml 66 1323 μmol/l (μmol/l = μg/ml x 6.616) 1.00 6.00 g/dl 10.0-60.0 g/l (g/l = g/dl x 10) Therapeutic: 670
More informationA validation study of after reconstitution stability of diabetes: level 1 and diabetes level 2 controls
A validation study of after reconstitution stability of diabetes: level 1 and diabetes level 2 controls Shyamali Pal R B Diagnostic Private Limited, Lake Town, Kolkata, India INFO ABSTRACT Corresponding
More informationUpdate: Body Fluid Testing. Fernando San Gil
Update: Body Fluid Testing Fernando San Gil Background Notes - 1 Year Significant moments in IVD 2013 NATA and the TGA publish new validation and registration requirements for in-house IVDs and for in-house
More informationBreakout Session C: Harmonisation of the Alert Table.
Breakout Session C: Harmonisation of the Alert Table. RCPA-AACB High Risk Results Working Party Andrew Georgiou Craig Campbell Grahame Caldwell Hans Schneider Penelope Coates Que Lam Rita Horvath Robert
More informationTEST LIST SAMPLE REQUIREMENT. 1 ml serum None
ALBUMIN TEST NAME ALKALINE PHOSPHATASE ALLERGY PROFILE, FOOD 30 allergens ALLERGY PROFILE, INHALANT 30 Allergens ALT AMYLASE ANA ANTI- TG ANTI-GLIADIN IGG ANTI-GLIADIN IGA ANTI-HBS ANTI-HCV ANTI-TPO APOLIPOPROTEIN
More informationConfirmation - A Practical Approach
Data Mining i for Reference Interval Confirmation - A Practical Approach Graham Jones Chemical Pathologist St Vincent s Hospital, Sydney AACB Webinar 5 th June 2013 Summary A little (more) background Current
More informationCLINICAL CHEMISTRY REAGENTS. Product Profile
Product Profile Why Clinical Chemistry Reagents? Quantitative determination of specific analytes associated with various types of disease. Diagnosis Identifying a disease already present Prognosis Forecasting
More informationDefine performance goals in standardization: Is fitness for medical purpose the key?
Define performance goals in standardization: Is fitness for medical purpose the key? 7th CIRME International Scientific Meeting Metrological traceability and assay standardization Stresa, May 24th, 2013
More informationEvaluation of Cheongmeak DCS TM Reagents for Chemistry Analyzers
임상검사와정도관리 J Lab Med Qual Assur 2010 ; 32:197-204 ISSN 1225-097X Evaluation of Cheongmeak DCS TM Reagents for Chemistry Analyzers Kyeong Seob Shin, Taek Eun Jeong, and Bo Ra Son Department of Laboratory
More informationEQAS. Hemoglobin Program (BC80) Cycle 12: December 2014 December 2015 Sample No: 1 Sample Date: 17 Dec 14. Exceptions. Customer Information
(BC80) : December 2014 December 20 Exceptions None at this time. Legend: No Warnings Missing Result Late Results < < > * Amended Result (per participant s request) News Customer Information Please refer
More informationCERTIFICATE OF ACCREDITATION
CERTIFICATE OF ACCREDITATION In terms of section 22(2) (b) of the Accreditation for Conformity Assessment, Calibration and Good Laboratory Practice Act, 2006 (Act 19 of 2006), read with sections 23(1),
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Biochemistry Department University Hospital of North Durham Durham County Durham DH1 5TW Contact: Dr Tim Lang Tel: +44 (0) 191 333 2694 Fax:
More informationEvaluation of VACUETTE SECONDARY Tubes
Evaluation of VACUETTE SECODARY Tubes Background VACUETTE SECODARY Tubes are used as a secondary container for aliquoting, storing and transporting blood, blood components and urine from the primary tube
More informationCERTIFICATE OF ACCREDITATION
CERTIFICATE OF ACCREDITATION In terms of section 22(2) (b) of the Accreditation for Conformity Assessment, Calibration and Good Laboratory Practice Act, 2006 (Act 19 of 2006), read with sections 23(1),
More informationSydPath Reference Intervals for Clinical Trials (Contract Pathology Unit) Unauthorised Copy
HAEMATOLOGY APTT 1 150 M 25 35 sec APTT 1 150 F 25 35 sec Basophils Cord 2 weeks M 0.0 0.4 10^9/L Basophils Cord 2 weeks F 0.0 0.4 10^9/L Basophils 2 wks 3 mths M 0.0 0.2 10^9/L Basophils 2 wks 3 mths
More informationWhy Traceability Matters to Patients?
Why Traceability Matters to Patients? (and you are all patients) Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney JCTLM Members and Stakeholders meeting, Paris 2017 Acknowledgements
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationTest Result Reference Range Flag
Date of Last Result Test Result Reference Range Flag Dec 07, 2016 25-Hydroxy Vitamin D Total 53 ng/ml 30-100 ng/ml Activated Partial Thromboplast Time Alanine Aminotransferase (ALT/SGPT) 25 sec 24-35 sec
More informationSpecial issue: Six Sigma metrics Original papers
Special issue: Six Sigma metrics Original papers Risk analysis and assessment based on Sigma metrics and intended use Yong Xia 1, Hao Xue 1, Cunliang Yan 1, Bowen Li 2, ShuQiong Zhang 1, Mingyang Li 1,
More informationThis supplementary material has been provided by the authors to give readers
Supplementary Online Content LI D, Radulescu A, Shrestha RT, et al. Association of biotin ingestion with performance of hormone and nonhormone assays in healthy adults. JAMA. doi:1.11/jama.217.1375 efigure
More informationThe Whats and Hows of Reference Intervals. Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney
The Whats and Hows of Reference Intervals Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney Surabaya Indonesia 2016 Acknowledgements Reference Intervals - Summary What are they
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More informationMultiphasic Blood Analysis
Understanding Your Multiphasic Blood Analysis Test Results Mon General thanks you for participating in the multiphasic blood analysis. This test can be an early warning of health problems, including coronary
More informationQUALITROL 2H Insert. 01 Inglês - Ref.: 72. Ref.:72. Precautions and warnings
QUALITROL 2H Insert Ref.:72 Lot 6002 Expiration 2019/08/23 Precautions and warnings Qualitrol 2H is for in vitro diagnostic use only. Attention. It is suggested to verify carefully if the lot number pressed
More informationEvaluation Report of the Pneumatic Tube Transport System (PEVCO) connecting Dialysis Hospital to. Mubarak Hospital. Dr.
5 Evaluation Report of the Transport System (PEVCO) connecting Dialysis Hospital to Mubarak Hospital Dr. Anwar AlAnjeri Senior Registrar Clinical Biochemistry Laboratory Mubarak Hospital Introduction:
More informationLIQUID ASSAYED CHEMISTRY CONTROL PREMIUM PLUS - LEVEL 1 (LIQ CHEM ASY PREMIUM PLUS 1)
0086 LIQUID ASSAYED CHEMISTRY CONTROL PREMIUM PLUS - LEVEL 1 (LIQ CHEM ASY PREMIUM PLUS 1) CAT. NO. LAL 4213 LOT NO. 238UL SIZE: 12 x 5 ml EXPIRY: 2018-04-28 GTIN: 05055273209006 INTENDED USE This product
More informationBASIC METABOLIC PANEL
Update 2/12/2018 BASIC METABOLIC PANEL CPT 80048 Stability: 3 days at 15-25 C; 7 days at 2-8 C; > 7 days at -70 C Colorimetric Assay, Rate reaction, ISE Components: BUN, Calcium, Chloride, CO2, Creatinine,
More informationThe Integrated Cardiovascular Clinical Network CHSA
The Integrated Cardiovascular Clinical Network CHSA Roche cobas b 101 HbA1c and Lipids Evaluation July 2013 Introduction Cardiovascular disease (CVD) is the leading cause of mortality in Australia, accounting
More informationIndividual Lab Report Ci-Trol Nov,2016. Abnormal Fibrinogen (mg/dl) Abnormal Fbg Control - Lot# LFC Your Lab
Individual Lab Report Ci-Trol Nov,2016 ST VINCENT MEDICAL CENTER LABORATORY(LAB# 7300 ) 2131 WEST THIRD STREET LOS ANGELES CA USA 90057 Abnormal Fibrinogen (mg/dl) Abnormal Fbg Control - Lot# LFC SYSMEX
More informationClinician Blood Panel Results
Page 1 of 8 Blood Panel - Markers Out of Range and Patterns (Pattern: proprietary formula using one or more Blood Markers) Blood Panel: Check for Markers that are out of Lab Range ***NOTE*** Only one supplement
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationLaboratory Medicine Standardization Activity in Japan
JCTLM 15/11/2005 Sevres, Paris oratory Medicine Standardization Activity in Japan National Institute Metrology of Japan (NMIJ) Koichi Chiba Fujirebio Inc. Katsuhiko Yamamoto University of Tsukuba Katsuhiko
More informationWhat information on measurement uncertainty should be communicated to clinicians, and how? Mario Plebani
What information on measurement uncertainty should be communicated to clinicians, and how? Mario Plebani OUTLINE OF TALK Uncertainty in medicine and shared decision making Measurement uncertainty in laboratory
More information1 PROTOCOL. Comparison Study Summary
Comparison Study Summary OnSite Health 210 S. Michigan Street, Suite 110 South Bend, IN 46601 574-243-5108 ext. 203 July 27, 2015 1 PROTOCOL This internal evaluation was conducted on July 17 & 20, 2015
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationDelta Check Calculation Guide
Delta Check Calculation Guide National Technology 2017, All Rights Reserved By Senior Scientific Researcher, Asmaa Taher Table of Contents Definition... 2 Purpose... 2 Delta Check Research Studies... 2
More informationICL Integrative Laboratory Services Test Menu Contact ICL Client Care x300
Alletess Food Sensitivity Fingerstick 96 Foods IgG with or without Wellness Program 184 Foods IgG with or without Wellness Program Alletess Food Allergy/Sensitivity Serum 96 Foods IgG with or without Wellness
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More information